Clinical trial NCT05622591: ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
Official title: Dose Escalation Study to Evaluate the Safety and Tolerability of ELU001 in Pediatric Patients Who Have Relapsed and/or Refractory CBFA2T3::GLIS2 Positive Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
AML, Childhood
Relapsed Pediatric AML
Refractory Pediatric AML
Keywords: CBFA2T3-GLIS2
CBFA2T3::GLIS2
Refractory
Folate Receptor alpha
Acute Myeloid Leukemia
ELU001
Exatecan
C'Dot drug conjugate
C-Dot
C'Dot
Childhood
Nanoparticle
Folate Receptor
AML
Relapsed
Lead sponsor: Elucida Oncology
Sponsor class: INDUSTRY
First posted: 2022-11-18
Enrollment: 0
Sex: ALL
Minimum age (years): 1
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Dose Escalation
Primary purpose: TREATMENT

Brief summary: This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRα) (a protein on the surface of leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back after treatment. Refractory means the cancer does not respond to treatment.

Detailed description: This study was planned as a Dose Escalation Safety Study to identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D). This study will also evaluate the tolerability of ELU001.

ELU001 is not a drug approved by the FDA (Food and Drug Administration) yet.

Eligibility criteria: Key Inclusion Criteria:

Patients must meet the following criteria to enroll in this study:

* Infants (\>1 month) and children (≤9 years) at time of enrollment.
* Relapsed or refractory CBFA2T3::GLIS2 positive AML
* CNS1 or CNS2 during screening
* Performance Status: Lansky ≥ 50
* Adequate Organ Function including liver, kidney, and heart

Key Exclusion Criteria:

Patients who meet any of the following are not eligible to enroll in this study:

* CNS3 Disease
* AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes.
* Acute promyelocytic leukemia.
* Clinically significant active or chronic corneal disorder, particularly corneal epitheliopathy or any eye disorder that may predispose patient to this condition, or unable to comply with an age-appropriate ophthalmologic examination.
* Prior treatment with folate receptor-targeting anti-cancer agent(s) ≤ 21 days (or 2 half-lives must have elapsed before enrollment, whichever is longer), or received investigational anti-cancer treatment ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, prior to starting study drug, whichever is shorter.

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ELU001
timeFrame: 28 days
Secondary outcomes:
measure: Evaluate preliminary anti-leukemic activity of ELU001
timeFrame: First dose of study drug until 42 days after last cycle.
measure: Characterize the pharmacokinetics of ELU001
timeFrame: First dose of study drug until 42 days after last cycle.
measure: Characterize the immunogenicity of ELU001
timeFrame: First dose of study drug until 42 days after last cycle.
Other outcomes:
Locations:
Study officials:
References: